For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
Weight Change after Globus Pallidus Internus or Subthalamic Nucleus Deep Brain Stimulation in Parkinson’s Disease and DystoniaMills K.A.a, d · Scherzer R.c, d · Starr P.A.b, d · Ostrem J.L.a, d
Departments of aNeurology and bNeurosurgery, Surgical Movement Disorders Center, University of California San Francisco, cDepartment of Medicine, University of California San Francisco, and dSan Francisco Veterans’ Affairs Medical Center, San Francisco, Calif., USA Corresponding Author
Jill Ostrem, MD
Surgical Movement Disorders Center, University of California San Francisco
1635 Divisadero Street, Suite 502
San Francisco, CA 94115 (USA)
Tel. +1 415 353 2311, E-Mail firstname.lastname@example.org
Background: Weight gain has been described in Parkinson’s disease (PD) patients after subthalamic nucleus (STN) deep brain stimulation (DBS). Objectives: We examined change in weight following DBS in both PD and dystonia patients to further investigate the role of disease and brain target (STN or globus pallidus internus, GPi) specificity. Methods: Data was retrospectively collected on 61 PD DBS patients (STN n = 31 or GPi n = 30) and on 36 dystonia DBS patients (STN n = 9 and GPi n = 27) before and after surgery. Annual change in body mass index (BMI) was evaluated with nonparametric tests between groups and multiple quantile regression. Results: PD patients treated with STN DBS had a small increase in median BMI while those with GPi had a small decrease in BMI. Dystonia patients treated with STN DBS had a greater increase in BMI per year compared to those treated with GPi DBS. Multivariable regression analyses for each disease showed little difference between targets in weight gain in those with PD, but STN target was strongly associated with weight gain in dystonia patients (STN vs. GPi, +7.99 kg, p = 0.012). Conclusions: Our results support previous reports of weight gain after DBS in PD. This is the first report to suggest a target-specific increase in weight following STN DBS in dystonia patients.
© 2012 S. Karger AG, Basel
Deep brain stimulation (DBS) is used to treat a variety of movement disorders, including Parkinson’s disease (PD), dystonia [1,2,3], and essential tremor [4,5,6]. PD patients typically have progressive weight loss [7,8] that is thought to be associated with elevated daily energy expenditure (EE). Interestingly, after bilateral [9,10,11,12] and even unilateral [13,14] subthalamic nucleus (STN) DBS, PD patients have been reported to typically gain weight. PD patients treated with STN DBS have body mass indices (BMI; weight in kilograms divided by height in square meters) that eventually approach those of age-matched healthy controls [15,16].
Recent studies describing weight gain after DBS in PD have focused on STN as the brain target [9,10,11,12,13,16]. Previous studies looking at pallidotomy [17,18,19] and pallidal DBS [20 ]have shown less pronounced weight gain in comparison to the STN DBS studies. A few studies have directly compared weight changes in PD patients treated with STN or globus pallidus internus (GPi) DBS [20,21,22]. All of these studies were nonrandomized in target selection except one unilateral treatment study , which did not find a statistically significant difference in weight between the two target groups. The current study is the first to examine the differential effects of DBS target on weight gain in PD patients randomized to receive either bilateral STN or GPi DBS to further test the hypothesis of weight gain after DBS being due to a correction of an underlying alteration in EE specific to PD. Unique to this study, we also evaluated weight gain in a group of dystonia patients receiving STN or GPi DBS, whose disease course is not typically associated with progressive weight loss.
PD patients who met standard criteria for DBS surgery were randomized to receive either STN or GPi DBS . Dystonia patients were not randomized to target and included patients enrolled in a recent trial evaluating the use of STN DBS in dystonia  and additional dystonia patients who received GPi DBS at our center. Institutional Review Board approval was obtained both from the University of California San Francisco (UCSF) Committee on Human Research and the San Francisco Veterans’ Affairs Medical Center (Institutional Review Board No. 10-03456). Patients were included as subjects if they underwent either subthalamic or pallidal DBS at the UCSF or the San Francisco Veterans’ Affairs Medical Center for PD or primary dystonia, had presurgical height and weight measurements, had a postsurgical height and weight measurement at least 12 months after surgery, and were over 18 years of age. Patients were excluded if their stimulators were turned off for a period of more than 3 months at any time during the follow-up. Between the two time points used in this study, no patients were counseled or treated with specific dietary interventions outside normal care that may have been provided by their primary care physicians.
Data was collected retrospectively through chart review and stored on a secure server. In addition to the indication for DBS and the brain target, data for the following variables were collected at both the presurgical and postsurgical time points: preoperative weight (kilograms), preoperative height (centimeters), antiparkinsonian medications in PD patients (expressed in levodopa equivalent daily dose), age at surgery, sex, percent change in Burke-Fahn-Marsden Dystonia Rating Scale (BFM-DRS) scores in the dystonia patients, and amount of time between preoperative and postoperative time points (months). Medication usage in our dystonia population was not available postoperatively; thus, we could not include this as a covariate in our model. PD rating scales were not available at the time points when weight was collected either.
Baseline demographic and clinical characteristics were compared by target for each disease using the Wilcoxon rank sum test for continuous variables and Fisher’s exact test for categorical variables. Within-group tests of annual change in BMI were conducted using the Wilcoxon signed-rank test, and annual changes in BMI were compared between targets for each disease using the Wilcoxon rank sum test. For this part of the analysis, the yearly rate of weight gain was assumed to be constant despite differences in time to follow-up between the dystonia target groups.
We used multivariable quantile regression analyses to estimate the association of disease (PD vs. dystonia) and target (GPi vs. STN) with total change in weight, while controlling for potentially confounding factors, such as the amount of time between data collection points. Covariates in the model included age, gender, baseline BMI, time between pre- and postoperative weights, percent change in BFM-DRS (dystonia only) and levodopa equivalent daily dose (in PD only). Tests of the residuals found violations of normality and heteroscedasticity; therefore, we used quantile regression analyses to estimate the differences in weight change between disease and target . All analyses were conducted using Stata version 11 (Stata Corp., College Station, Tex., USA).
The study included 61 patients with PD and 35 with dystonia, whose baseline characteristics are presented in table 1. Among participants with PD, 30 had GPi and 31 had STN DBS, with a majority of PD participants being male (48 M/13 F). The PD patients’ average age was 61 years, and a follow-up weight obtained at an average of 38 months. Although PD subjects with GPi were heavier than those with STN on average (84 vs. 74 kg, p = 0.0078), their baseline BMIs were only slightly higher (27 vs. 25, p = 0.21) compared to those treated with STN, due to differences in height (1.77 vs. 1.71 m, p = 0.06).
Among dystonia patients, 27 had GPi and 9 had STN DBS implants, with similar proportions of males and females (18 M/18 F). Those treated with GPi DBS were slightly younger on average (45 vs. 48 years, p = 0.68) and had a somewhat lower weight (72 vs. 84 kg, p = 0.065) and BMI (24 vs. 28, p = 0.065) compared to those with STN DBS, though none of these differences were statistically significant. In dystonia patients, the amount of time between the baseline and collection of postoperative data points was longer in the GPi DBS group than in the STN DBS group (27 vs. 18 months, p = 0.023).
The distribution of annual change in BMI is presented in figure 1. The difference between targets in annual change in BMI was much larger for the dystonia patients than for the PD patients (target-by-disease interaction, p = 0.012). Therefore, we stratified our analyses by disease and compared the two brain targets in both PD and dystonia separately (tables 2, 3).
Among those with PD, there was a nonstatistically significant difference in median annual change in weight (0.93 kg/year, p = 0.071) but a statistically significant difference in change in BMI (0.53 points/year, p = 0.037) by target. Those treated with GPi DBS had a small, nonstatistically significant decrease in weight (–0.04 kg/year, 0%/year, p = 0.59) and BMI (–0.14 points/year, p = 0.32), while those treated with STN had a trend towards an increase in weight (+0.89 kg/year, 1%/year, p = 0.079) and BMI (+0.39 points/year, p = 0.055). Dystonia patients treated with STN DBS had a greater increase in weight (6.10 kg/year, 7%/year, p = 0.028) and BMI (1.81 points/year, p = 0.021), while those treated with GPi DBS showed only a small increase in weight (0.40 kg/year, 1%/year, p = 0.68) and BMI (0.14 points/year, p = 0.56) with a statistically significant difference in median weight gain (median 5.70 kg/year, p = 0.027) and BMI increase (1.67 points/year, p = 0.020) found between the two targets. Of the GPi DBS dystonia patients, 16 had an increase in BMI (range: 0.01–3.82 points/year) while 11 had a decrease in BMI (range: –0.04 to –1.47 points/year). In the dystonia patients with STN DBS, 7 had an increase in BMI (range: 1.09–7.53 points/year) and only 2 saw a decrease in BMI (range: –0.085 to –0.93 points/year). In the dystonia patients who received GPi DBS, 71% of those with generalized dystonia gained weight, while 15% of those with focal or segmental (craniocervical) dystonia gained weight. In dystonia patients with STN DBS, 100% of the generalized dystonia patients gained weight while 71% of the segmental (craniocervical) patients gained weight.
Multivariable median regression analyses, stratified by disease, were performed to control for potentially confounding factors (table 4). Among those with PD, baseline BMI was negatively associated with annual change in BMI (–0.78 kg per baseline BMI per year, p = 0.009), demonstrating that those with lower BMI at baseline were more likely to gain weight after surgery. There were no significant associations with other factors in the model (age, time to follow-up, gender, or change in levodopa equivalent daily dose; p = 0.99) in PD patients. The STN target was associated with slightly greater weight gain compared with the GPi target, although the difference between targets did not reach statistical significance (+3.09 kg, p = 0.26). In the patients with dystonia, those treated with STN DBS gained a median of 7.99 kg more than those treated with GPi DBS (95% CI: 1.87–14.11, p = 0.012). Baseline BMI in dystonia showed a trend toward a negative association with weight gain (–0.39 kg per preoperative BMI point, p = 0.15), but the effect size was small and the association did not reach statistical significance. Dystonia patients also showed a trend toward more weight gain in women (2.03 kg more than men, p = 0.38). Percent improvement in BFM-DRS showed a trend toward having a small positive relationship with annual change in BMI (0.034 kg per 1% improvement, 95% CI: –0.025 to 0.094, p = 0.25). Even with a reasonable clinical improvement of 50% in BFM-DRS after DBS, this would only give an effect size of 1.7 kg, which is still overshadowed by the effect size of target.
This is the first study to look at change in weight following treatment with two different DBS targets (STN and GPi) and in two different patient populations (PD and dystonia). While previous studies have described weight change following DBS for PD, no previous studies have evaluated weight change in dystonia patients with DBS as a separate group.
In this study, as has been shown previously, PD patients receiving bilateral DBS (regardless of target) showed a significant increase in BMI per year after surgery. The relative change in BMI was not as great as reported in other studies [9,10,13,16,21] with the exception of that of Strowd et al.  which showed a similar modest weight gain. When weight change was compared between STN and GPi patients in another prospective study, there was weight gain seen in both groups (mean of 5.7 kg in 6 months in the STN group and a mean of 1.7 kg in 6 months in the GPi group ), which was almost 10-fold of that seen in our study when these values are converted to annual weight change. However, this group reported weight gain >10 kg in 4 of 32 (12.5%) STN patients and 1 of 14 (7%) GPi patients, which was similar to the 5 of 31 (19%) and 1 of 30 (3.3%) in our STN and GPi patients, respectively. In another study which reported weight gain in both targets 1 year after surgery, there was a weight gain of >10 kg in 6 out of 16 (38%) STN patients and 3 of 11 (27%) GPi patients . In comparison to the studies with more weight gain, our sample of PD patients appeared to have a greater proportion of males and a slightly higher baseline weight.
Interestingly, even though PD patients receiving STN DBS had a higher median weight gain compared to those treated with GPi DBS, the effect of target did not meet statistical significance using a multivariable regression analysis when baseline BMI was considered as a predictor of weight gain. The weak effect of brain target on the degree of weight gain in PD patients was also found in a similar study when PD patients were randomized to receive unilateral DBS in either target (GPi or STN) and showed no difference in weight gain between the two brain targets . This finding conflicts with the study by Sauleau et al. , where PD patients were not randomized to DBS target but were preferentially treated with GPi DBS rather than STN DBS if ‘cognitive impairment’ was present. They found a statistically significant weight gain (mean of 5.7 kg in 6 months, p < 0.0001) in the bilateral STN group, while there was a nonstatistically significant trend toward mild weight gain (mean of 1.7 kg in 6 months, p = 0.384) in the bilateral GPi group . As mentioned previously, the study of Volkmann et al.  reported a difference in the number of patients in each target group who gained >10 kg that was similar to that seen in our study as well as the study by Sauleau et al. . Considering the number of patients with a large amount of weight gain in each group leads us to conclude that despite the lower median amount of weight gain seen in our study population, the target-specific weight gain after DBS for PD is similar to that which has been reported by other authors.
Multivariable quantile regression analysis in PD patients revealed trends toward a moderate effect of target and an even smaller effect of sex on the degree of weight gain, with the STN target and female sex promoted more weight gain. Baseline (pre-DBS) BMI was the only variable to show a statistically significant (but small) effect on weight gain in this model. When baseline BMI is removed from the regression analysis, the effect of target becomes stronger (4.18 kg greater in STN, 95% CI: 0.75–7.62, p = 0.018), suggesting that this difference might be explained by the effect of preoperative BMI. Since our STN and GPi DBS PD patients had a similar preoperative BMI, it may be that underweight patients receiving STN DBS are more likely to gain weight than underweight patients receiving GPi DBS. Alternatively, the difference between targets in median baseline BMI (by 2 points, p = 0.21) may have been statistically significant in a larger sample, in which case the contribution of the ‘baseline BMI effect’ to the ‘target effect’ could be explained by a difference between the two target groups in baseline BMI.
Dystonia patients treated with STN DBS also experienced a statistically significant weight gain after DBS which was not found in the dystonia patients treated with GPi DBS. This target-dependent difference in annual increase in BMI was much larger in the dystonia patients than in the PD patients, and remained large and statistically significant even after accounting for variability in patient age, gender, percent improvement in BFM-DRS, length to follow-up, and baseline BMI between the two groups (table 4). Only one other study included dystonia patients treated with GPi DBS in their report of weight gain after surgery, and while their DBS population as a whole gained weight, the number of dystonia patients was not large enough to analyze as a separate group . To our knowledge, this study is the first to evaluate weight change following both GPi DBS and STN DBS in dystonia.
The mechanism for weight gain seen after DBS is still debated [13,15,22]. Most studies have focused on the PD population with proposed explanations for this effect after STN DBS including: decreased dosage of PD medications, an increase in dietary energy intake, a decrease in muscle activity as tremor or muscle rigidity, a decrease in dyskinesias , a central mechanism of alteration in metabolism mitigated by the direct effects of stimulation on nearby brain structures [15,16,27], and/or a decrease in energy expenditure related to improvement in motor fluctuations . The latter of these hypotheses has been promoted by Montaurier et al. , where PD patients underwent highly controlled calorimetry to measure EE before and after STN DBS surgery. Daily EE was significantly lower after STN DBS; however, a high preoperative UPDRS III score was associated with less change in daily EE. The drop in EE following DBS was not found to be predictive of postoperative weight gain. There was no correlation between weight gain and reduction of PD medications or with improvement in UPDRS IV score (measures severity of dyskinesias and motor fluctuations). While it has been proposed that an improvement in motor symptoms correcting EE  allows for weight gain , this has not necessarily been shown in the Montaurier study or other studies assessing a correlation between motor improvement and weight change [9,10]. This led the authors to conclude that post-DBS weight gain may be due to improvement in spontaneous motor fluctuations, but that they could not rule out the possibility of an effect on central regulation of energy expenditure, possibly through stimulation of the nearby thalamus. This study only used STN DBS patients, so it is unclear whether or not this decrease in EE would also be seen in GPi DBS.
The observation from our study that weight gain seems relatively site specific in dystonia supports a hypothesis of a centrally mediated change in energy metabolism as a result of DBS, especially given the similar motor outcomes in both targets (47.2 vs. 45.5% improvement in BFM-DRS in GPi and STN, respectively). Because dystonia patients are not generally known to experience chronic wasting, the effect of subthalamic stimulation on weight occurs even without the presence of chronic weight loss that is typical of PD [7,8,29]. This suggests that the effect of STN DBS may be a stimulation-induced side effect rather than a ‘regression toward the mean’ as it is considered in PD. This idea is also supported by a recent study showing a significant change in hypothalamic hormonal function following STN DBS . It is also possible that the weight gain seen in dystonia patients may be due to site-specific changes in impulse control [30,31] and have an effect on eating habits, although multiple studies have not shown an association between increase in energy (dietary) intake and post-DBS weight gain in PD [15,21].
Weaknesses of this study include the retrospective study design, the lack of randomization of brain target in the dystonia population, the relatively small sample size of dystonia patients treated with STN DBS, and the lack of prospectively collected weights at multiple predefined time points. While we do not have other time points to evaluate this possibility given the retrospective nature, other studies have reported sustained weight gain throughout the 1–2 years of prospective follow-up [9,13,26], highlighting that changes in weight after DBS are typically stable. Also, the mean total change in weight (irrespective of time to follow-up) in the GPi dystonia group was 0.56 kg while it was 8.62 kg in the STN dystonia group, indicating that unless the GPi dystonia patients lost weight during their increased length of follow-up, the yearly rate likely represents a consistent trend describing weight fluctuations in both sets of patients. To further address the difference in follow-up time between the GPi and STN dystonia groups, the time between pre- and postoperative weight recordings was evaluated as an independent variable in a multivariable quantile regression analysis and did not have a significant effect on the amount of weight gain in either brain target group (table 4). Our dystonia patients were also younger and more often female than our PD patients; however, results were similar in unadjusted and adjusted analyses, and there was no association of gender or age with weight gain in multivariable analysis. Another weakness is the lack of information of daily energy intake, which could be altered in either PD or dystonia. Several studies have shown no increase in daily energy intake after STN DBS for PD [9,10,12,15,19], but there is no data confirming that this is also the case in dystonia.
While the retrospective design and small sample size of this study should be taken into consideration when interpreting the study’s findings, the potential for target-specific effects on weight introduces another important variable (along with many other factors) to consider when making a decision about the most appropriate DBS brain target. PD and dystonia patients should be counseled that STN DBS may result in some weight gain after surgery, though the impact of this weight gain on overall health is unknown in these patients. Future prospective DBS studies using alternative brain targets for dystonia should include weight as a variable to better understand the short and long-term impact it may have on health.
The authors would like to acknowledge Larisa Collins for her help with data collection and Leslie Markun for her help with the review of the manuscript.
Kelly Mills is funded by the University of California San Francisco Clinical and Translational Science Institute Resident Research Funding Award, he is also Co-PI on a grant from the Clinical and Translational Science Institute Strategic Opportunities Support Novel Clinical/Translational Methods Catalyst Awards, NIH/NCRR UCSF-CTSI grant No. UL1RR024131. Philip Starr is a consultant for Medtronic Inc. and Boston Scientific Inc. and holds a research grant from MRI Interventions Inc. (formerly called Surgivision). Jill Ostrem is a consultant for Ipsen Inc., Merz Inc., Boston Scientific Inc. and is on an advisory board for Ipsen Inc. and Merz Inc. She has received honoraria from Medtronic Inc. and Allergan Inc. and currently receives research grant funding from St. Jude Medical and MRI Interventions Inc. (formally called SurgiVision). She is also mentor for a fellowship grant from Medtronic Inc.
Jill Ostrem, MD
Surgical Movement Disorders Center, University of California San Francisco
1635 Divisadero Street, Suite 502
San Francisco, CA 94115 (USA)
Tel. +1 415 353 2311, E-Mail email@example.com
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.